Non-genetic neuromodulation with graphene optoelectronic actuators for disease models, stem cell maturation, and biohybrid robotics
- PMID: 40835596
- PMCID: PMC12368249
- DOI: 10.1038/s41467-025-62637-6
Non-genetic neuromodulation with graphene optoelectronic actuators for disease models, stem cell maturation, and biohybrid robotics
Abstract
Light can serve as a tunable trigger for neurobioengineering technologies, enabling probing, control, and enhancement of brain function with unmatched spatiotemporal precision. Yet, these technologies often require genetic or structural alterations of neurons, disrupting their natural activity. Here, we introduce the Graphene-Mediated Optical Stimulation (GraMOS) platform, which leverages graphene's optoelectronic properties and its ability to efficiently convert light into electricity. Using GraMOS in longitudinal studies, we found that repeated optical stimulation enhances the maturation of hiPSC-derived neurons and brain organoids, underscoring GraMOS's potential for regenerative medicine and neurodevelopmental studies. To explore its potential for disease modeling, we applied short-term GraMOS to Alzheimer's stem cell models, uncovering disease-associated alterations in neuronal activity. Finally, we demonstrated a proof-of-concept for neuroengineering applications by directing robotic movements with GraMOS-triggered signals from graphene-interfaced brain organoids. By enabling precise, non-invasive neural control across timescales from milliseconds to months, GraMOS opens new avenues in neurodevelopment, disease treatment, and robotics.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: A.S. and E.M. are co-founders of Nanotools Bioscience, a company focused on exploring the optoelectronic properties of graphene for biomedical applications and developing the tools and technologies for enabling these applications. E.M. is the inventor and applicant on patents (US10137150B2, US10688127B2, CN106458601B, JP6635383B2, EP3157866B1) related to the graphene-based optical stimulation technology, and its applications, including its use for driving activity-dependent maturation of stem cell-derived cells. A.R.M is a co-founder and has an equity interest in TISMOO, a company dedicated to genetic analysis and brain organoid modeling focusing on therapeutic applications customized for autism spectrum disorder and other neurological disorders with genetic origins. The terms of this arrangement have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies. E.M., A.S., and A.R.M. declare no other competing interests. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Inclusion & Ethics Statement: This study does not involve experiment involving animals, human participants, or clinical samples. All research presented in this manuscript was conducted in accordance with ethical guidelines and best practices for scientific integrity and responsible collaboration. No part of the study involved research in resource-limited settings or populations from low- or middle-income countries. All contributors to this work were properly credited for their efforts and intellectual input.
Figures
References
MeSH terms
Substances
Grants and funding
- R01 MH127077/MH/NIMH NIH HHS/United States
- R43 MH124563/MH/NIMH NIH HHS/United States
- R01 MH123828/MH/NIMH NIH HHS/United States
- 1R01ES033636/U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS)
- 1R43AG076088/U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)
- 1R01MH128365/U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
- 1R43NS122666/U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- MH123828/U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
- R01 NS123642/NS/NINDS NIH HHS/United States
- S10 OD026929/OD/NIH HHS/United States
- R01 ES033636/ES/NIEHS NIH HHS/United States
- R56 MH128365/MH/NIMH NIH HHS/United States
- R01NS123642/U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- R43 AG076088/AG/NIA NIH HHS/United States
- R43 NS122666/NS/NINDS NIH HHS/United States
- R01 NS105969/NS/NINDS NIH HHS/United States
- DISC2-13866/California Institute for Regenerative Medicine (CIRM)
- R44 DA050393/DA/NIDA NIH HHS/United States
- 5R44DA050393/U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA)
- 1R43MH124563/U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH)
LinkOut - more resources
Full Text Sources
